We are tempted to speculate that these findings may help to explain why some patients with FISH-positive tumours who shed Her2/neu EDC but express relatively low levels of surface Her2/neu may experience suboptimal responses to trastuzumab therapy in vivo. The gene discussed is ERBB2; the disease is neoplasm.